China · Delayed Price · Currency is CNY Guanhao Biotech Statistics
Total Valuation
Guanhao Biotech has a market cap or net worth of CNY 3.01 billion. The enterprise value is 2.82 billion.
| Market Cap | 3.01B |
| Enterprise Value | 2.82B |
Important Dates
The last earnings date was Thursday, October 29, 2026.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Guanhao Biotech has 274.70 million shares outstanding. The number of shares has increased by 1.25% in one year.
| Current Share Class | 274.70M |
| Shares Outstanding | 274.70M |
| Shares Change (YoY) | +1.25% |
| Shares Change (QoQ) | -3.34% |
| Owned by Insiders (%) | 1.82% |
| Owned by Institutions (%) | 7.41% |
| Float | 209.30M |
Valuation Ratios
The trailing PE ratio is 217.11.
| PE Ratio | 217.11 |
| Forward PE | n/a |
| PS Ratio | 8.72 |
| PB Ratio | 5.10 |
| P/TBV Ratio | 4.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 300.45 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 207.62 |
| EV / Sales | 8.17 |
| EV / EBITDA | 62.79 |
| EV / EBIT | 214.92 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.94, with a Debt / Equity ratio of 0.21.
| Current Ratio | 2.94 |
| Quick Ratio | 2.13 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 2.76 |
| Debt / FCF | n/a |
| Interest Coverage | 10.65 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on invested capital (ROIC) is 0.30%.
| Return on Equity (ROE) | 0.21% |
| Return on Assets (ROA) | 1.00% |
| Return on Invested Capital (ROIC) | 0.30% |
| Return on Capital Employed (ROCE) | 1.80% |
| Weighted Average Cost of Capital (WACC) | 5.50% |
| Revenue Per Employee | 644,583 |
| Profits Per Employee | 25,369 |
| Employee Count | 535 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.19 |
Taxes
In the past 12 months, Guanhao Biotech has paid 9.15 million in taxes.
| Income Tax | 9.15M |
| Effective Tax Rate | 89.01% |
Stock Price Statistics
The stock price has decreased by -29.08% in the last 52 weeks. The beta is 0.27, so Guanhao Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -29.08% |
| 50-Day Moving Average | 11.29 |
| 200-Day Moving Average | 13.16 |
| Relative Strength Index (RSI) | 51.21 |
| Average Volume (20 Days) | 4,093,312 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guanhao Biotech had revenue of CNY 344.85 million and earned 13.57 million in profits. Earnings per share was 0.05.
| Revenue | 344.85M |
| Gross Profit | 258.06M |
| Operating Income | 13.11M |
| Pretax Income | 10.28M |
| Net Income | 13.57M |
| EBITDA | 33.62M |
| EBIT | 13.11M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 222.53 million in cash and 123.94 million in debt, with a net cash position of 98.59 million or 0.36 per share.
| Cash & Cash Equivalents | 222.53M |
| Total Debt | 123.94M |
| Net Cash | 98.59M |
| Net Cash Per Share | 0.36 |
| Equity (Book Value) | 589.51M |
| Book Value Per Share | 2.56 |
| Working Capital | 250.50M |
Cash Flow
In the last 12 months, operating cash flow was 10.01 million and capital expenditures -29.79 million, giving a free cash flow of -19.78 million.
| Operating Cash Flow | 10.01M |
| Capital Expenditures | -29.79M |
| Depreciation & Amortization | 20.51M |
| Net Borrowing | 2.91M |
| Free Cash Flow | -19.78M |
| FCF Per Share | -0.07 |
Margins
Gross margin is 74.83%, with operating and profit margins of 3.80% and 3.94%.
| Gross Margin | 74.83% |
| Operating Margin | 3.80% |
| Pretax Margin | 2.98% |
| Profit Margin | 3.94% |
| EBITDA Margin | 9.75% |
| EBIT Margin | 3.80% |
| FCF Margin | n/a |
Dividends & Yields
Guanhao Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.03% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.25% |
| Shareholder Yield | -1.25% |
| Earnings Yield | 0.46% |
| FCF Yield | -0.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 16, 2015. It was a forward split with a ratio of 2.
| Last Split Date | Apr 16, 2015 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |